Journal of mucopolysaccharidosis and rare diseases

Association for Research of MPS and Rare Diseases (뮤코다당증연구학회)
권호 표지
DOI QR코드

DOI QR Code

Improving Patient Compliance with Biopharmaceuticals by Reducing Injection-Associated Pain

  • So, Jineon (Biopharmceutical R&D, LG Life Sciences)
  • Received : 2015.06.12
  • Accepted : 2015.06.22
  • Published : 2015.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Biopharmaceuticals, with their ability to treat many unmet needs, are seen as promising medications in diabetes mellitus, growth hormone deficiency, chronic renal failure, cancer, and rheumatoid arthritis. However, almost all biopharmaceuticals should be administrated by injection; IV, IM, and SC. In addition, these treatments are long term, and patients should receive frequent injections for many years. Patient compliance is therefore of critical importance to ensure treatment benefits. Therefore, the goal of drug product development should be focused on improving patient compliance by reducing injection-associated pain as well as stable formulation development. This review will suggest the kinds of factors that should be considered to minimize injection pain with regard to formulation, device, and injection procedures focused on SC injections.

Keywords

References

  1. Geary DF, Keating LE, Vigneux A, Stephens D, Hebert D, Harvey EA. Darbepoetin alfa (Aranesp) in children with chronic renal failure. Kidney Int 2005;68:1759-65. https://doi.org/10.1111/j.1523-1755.2005.00592.x
  2. Cummings EA, Reid GJ, Finley GA, McGrath PJ, Ritchie JA. Prevalence and source of pain in pediatric inpatients. Pain 1996;68:25-31. https://doi.org/10.1016/S0304-3959(96)03163-6
  3. Dahlquist LM, Gil KM, Armstrong FD, DeLawyer DD, Greene P, Wuori D. Preparing children for medical examinations: the importance of previous medical experience. Health Psychol 1986;5:249-59. https://doi.org/10.1037/0278-6133.5.3.249
  4. Frenken LA, van Lier HJ, Jordans JG, Leunissen KM, van Leusen R, Verstappen VM, Koene RA. Identification of the component part in an epoetin alfa preparation that causes pain after subcutaneous injection. Am J Kidney Dis 1993;22:553-6. https://doi.org/10.1016/S0272-6386(12)80928-0
  5. Laursen T, Hansen B, Fisker S. Pain Perception after Subcutaneous Injections of Media Containing Different Buffers. Basic Clin Pharmacol Toxicol 2006;98:218-21. https://doi.org/10.1111/j.1742-7843.2006.pto_271.x
  6. Kappelgaard AM1, Bojesen A, Skydsgaard K, Sjogren I, Laursen T. Liquid Growth Hormone: Preservatives and Buffers. Horm Res 2004;62(suppl 3):98-103. https://doi.org/10.1159/000080507
  7. Fransson J1, Espander-Jansson A. Local Tolerance of Subcutaneous Injections. J Pharm Pharmacol 1996;48:1012-5. https://doi.org/10.1111/j.2042-7158.1996.tb05892.x
  8. Gill HS1, Prausnitz MR. Does needle size matter? J Diabetes Sci Technol 2007;1:725-9. https://doi.org/10.1177/193229680700100517

Cited by

  1. Evaluation effectiveness of 0.1% nepafenac on injection-related pain in patients undergoing intravitreal Ozurdex injection vol.11, pp.None, 2019, https://doi.org/10.1177/2515841419861856
  2. Subcutaneous Injection of Drugs: Literature Review of Factors Influencing Pain Sensation at the Injection Site vol.36, pp.11, 2015, https://doi.org/10.1007/s12325-019-01101-6
  3. Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review vol.7, pp.4, 2020, https://doi.org/10.1007/s40744-020-00245-0